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Available online 13 April 2016BMSCs, also known as bone marrow-derivedmesenchymal stem cells, provide an excellent source of progenitor
cells for regenerative therapy. To assess whether osteoarthritis (OA) affects the regenerative potential of BMSCs
we compared the proliferation and differentiation potential as well as the surface marker expression proﬁle of
OA- versus control BMSCs.
BMSCs were isolated from bone marrow aspirates of n = 14 patients with advanced-stage idiopathic hip OA
(67± 6 years) and n= 15 healthy individuals (61 ± 4 years). Proliferation was quantiﬁed by total DNA content
and colony-forming-units of ﬁbroblastsmax (CFU-F) assay. Differentiation assays included immunohistology, cell-
speciﬁc alkaline phosphatase (ALP) activity, and osteogenic, chondrogenic as well as adipogenic marker gene
qRT-PCR. Expression of BMSC-associated surface markers was analyzed using ﬂow cytometry.
No signiﬁcant intergroup differences were observed concerning the proliferation potential, cell-speciﬁc ALP activity
as well as adipogenic and osteogenic differentiation marker gene expressions. Interestingly, SOX9 gene expression
levels were signiﬁcantly increased in OA-BMSCs after 14 days of chondrogenic stimulation (p b 0.01). The surface
markers CD73, CD90 and STRO-1 were elevated in relation to CD14, CD34 and CD45 in both groups (p b 0.0001).
Notably, OA-BMSCs showed signiﬁcantly increased CD90 (p b 0.01) and decreased CD166 (p b 0.001) levels.
Overall, the in vitro characteristics of BMSCs are not markedly inﬂuenced by OA. However, increased SOX9 and
CD90 as well as reduced CD166 expression levels in OA-BMSCs warrant further investigation. These data will
help to further understand the role of BMSC inOAand facilitate the applicationof autologous cell-based strategies
for musculoskeletal tissue regeneration in OA patients.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Differentiation1. Introduction
BMSCs, also known as bone marrow-derived mesenchymal stem
cells, can be easily isolated and culture expanded from bonemarrow as-
pirates and provide an excellent source of progenitor cells (Bianco et al.,
2008; Pittenger et al., 1999). They are one of the major cellular com-
pounds used for clinical bone tissue engineering — a therapeutic con-
cept aiming at site-speciﬁc tissue regeneration in patients suffering
from extended bone defects caused by e.g. trauma, tumor resection,
infection, degenerative joint disease, congenital deformities, and
periprosthetic bone loss (Rauh et al., 2011).paedics & Trauma Surgery and
earch, University Hospital Carl
erstr. 74, building 29, D-01307
dresden.de (H. Bretschneider).
. This is an open access article underOsteoarthritis (OA) represents the most frequent form of chronic
joint disease and a major cause of pain and disability affecting the
aging population with increasing prevalence. OA is the main indication
for total joint replacement (TJR) — the end-stage, non-biologic therapy
of OA performed over one million times annually worldwide resulting
in the life-long risk of implant failure due to aseptic (usually wear-
induced) or septic loosening albeit TJR being one of the most successful
current surgical procedures (Learmonth et al., 2007). Aswas just recent-
ly reviewed by Mobasheri et al. (2014), OA denotes one of the top ﬁve
causes of disability among non-hospitalized adults with currently
more than 55 million patients in the USA and Europe alone. Further-
more, OA is an important cause of disability-adjusted-life years world-
wide (Brooks, 2006). In OA, both cartilage, synovial, and bone tissues
and their respective cells are altered during disease progression
(Bijlsma et al., 2011). Recently, cellular changes in the subchondral
bone have been proposed to be associated with the onset of cartilage
degradation in OA (Intema et al., 2010). It is therefore of interest to
investigate the association of bone progenitor cell function and OA.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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cell-based regenerative therapy have OA as either primary disease or
comorbidity. As a prerequisite for musculoskeletal tissue reconstruction
autologous progenitor cell function is therefore key (The Swedish Hip
Arthroplasty Register, http://www.shpr.se/en/). In this context, the in-
ﬂuence of common donor comorbidities, such as OA, on BMSC function
should be extensively investigated.
We hypothesized that the regenerative potential of bone marrow
stromal cells derived from advanced-stage OA donors is altered and,
to this end, compared the proliferation and differentiation potential as
well as distinct surface marker expression patterns in these cells with
those of healthy, age-matched donors applying proliferation, differenti-
ation, and surface marker expression analyses.
2. Methods
2.1. Protocol design and patient cohort
Patients scheduled to receive THR due to idiopathic hip OA were al-
located to the OA group according to deﬁned inclusion/exclusion
criteria. Age-matched healthy donors were recruited and served as
control individuals. Informed consent of all participants was obtained.
Only patients with radiographic evidence for advanced OA of the hip
(Kellgren and Lawrence grade 3 or 4) were included (Kellgren and
Lawrence, 1963). Furthermore, OA was clinically objectiﬁed by use of
algofunctional indices (i.e. Western Ontario and McMaster Universities
OA index (WOMAC), Harris Hip Score (HHS), and EuroQol-5D (EQ-5D).
A total of 29 participants (9males, 20 females)were recruited. Of those,
n = 14 suffered from advanced-stage idiopathic OA of at least one
hip joint (mean age 67 ± 6 years) and n = 15 were age-matched
(mean age 61 ± 4 years), hematologically and musculoskeletally
healthy donors. The mean body mass index (BMI) was 27.5 kg/m2
and 25.0 kg/m2 in the OA and control groups, respectively. The study
was approved by the local institutional review board (protocol no.
EK203082008). All participants provided their written informed
consent.
2.2. Cell isolation and cultivation
Bonemarrow (BM) aspirations were performed either under gener-
al anesthesia prior to THR in the OA group or under local anesthesia
(10 mL xylocitin 0.5%, subcutaneously (sc)) and analgosedation
(1–2mgmidazolam, 1–3mgpiritramide, intravenously (iv)) in the con-
trol group. BMSCswere isolated from heparinized BM aspirates (50 cm3
each, 2 vol.%) obtained from the pelvic compartment of n = 14
advanced-stage idiopathic hip OA and n= 15 age-matched healthy do-
nors by density gradient separation and plastic adherence. The BM aspi-
rates were diluted 1:1 with phosphate buffered saline (PBS; 8.00 g/L
NaCl, 0.20 g/L KCl, 1.15 g/L Na2HPO4, 0.20 g/L KH2PO4 in Millipore-
water, pH 7.4), carefully layered onto a 12.5 mL Percoll cushion
(Biochrom AG, Berlin, Germany) and centrifuged at 2200 U/min and
20 °C for 30 min. Subsequently, the nucleated cell fraction at the inter-
face was collected, washed with PBS and resuspended in 10 mL
Mesencult® (Stem Cell Technologies, Cologne, Germany). Mononuclear
cells were plated at a density of 6–11 × 105 cells/cm2 and cultured
in basic medium (Dulbecco's Modiﬁed Eagle Medium (DMEM),
Invitrogen™, Karlsruhe, Germany) supplemented with 10% fetal calf
serum (FCS; Sigma-Aldrich®, Taufkirchen, Germany)without antibiotic
or antimycotic supplements. Cells were incubated at 37 °C in a humidi-
ﬁed atmosphere of 5% CO2 and medium was changed twice a week.
Adherent colonies were detached at 80–90% conﬂuency by treatment
with 0.05% trypsin/0.02% ethylenediaminetetraacetic acid (EDTA;
both Invitrogen™) and cryopreserved in DMEM containing 10%
dimethylsulfoxid (DMSO, Sigma-Aldrich®, Taufkirchen, Germany) and
20% FCS for later analysis. For all experiments low-passage (b3) and
mycoplasma-negative BMSC populations were used.2.3. Colony forming efﬁciency assay
For this assay, samples from n = 8 OA and n = 15 healthy
donors were analyzed in triplicate. Mononuclear cells were plated at
4 × 104/cm2 and cultured in non-hematopoietic medium (Miltenyi
Biotec GmbH, Bergisch Gladbach, Germany) for 14 days without change
of media. Subsequently, cells were stained with 5 mL Giemsa solution
(Merck, Darmstadt, Germany) for 30 min and washed three times
with distilled water followed by counting the number of colonies,
each of which was established by a single colony forming unit-
ﬁbroblast, CFU-F.2.4. Osteogenic differentiation and immunohistological analysis
BMSCs (passage 1) were plated at a density of 5.2 × 103/cm2 in du-
plicate and cultured with basic medium (DMEM, 10% FCS, 100 μg/mL
penicillin, 1000 μg/mL streptomycin (Invitrogen™)) in the absence or
presence of osteogenic supplements (100 nM dexamethasone, 10 mM
β-glycerophosphate, 50 μM ascorbic acid-2-phosphate) for up to
21 days. Cells were harvested in 1 mL PBS by careful use of a cell scrub-
ber after 1, 7, 14 and 21 days for marker gene expression analysis. To in-
vestigate alkaline phosphatase (ALP) activity BMSCs were plated at a
density of 4.5 × 103/cm2 and cultured for up to 14 days as described
above. After 1, 7 and 14 days BMSCs were washed with PBS and frozen
at−80 °C for later analysis. For biochemical determination of DNA con-
tent and alkaline phosphatase (ALP) activity, frozen samples were
thawed and cells were lysed in PBS containing 1% Triton X-100
(Sigma-Aldrich®) for 50 min on ice. DNA content was quantiﬁed
using the Quant-iT PicoGreen dsDNAAssay Kit (Invitrogen™) according
to the manufacturer's instructions and correlated with the cell number
using a calibration line. To measure ALP activity, lysates were incubated
with 1 mg/mL p-nitrophenylphosphate in 0.1 M diethanolamine
(pH 9.8) containing 1% Triton X-100 and 1 mM MgCl2 at 37 °C
for 30 min (all from Sigma-Aldrich®). The enzymatic reaction was
stopped with 1 M NaOH (Fluka Chemika, Taufkirchen, Germany) and
p-nitrophenolate was determined spectrophotometrically at 405 nm
(SpectraFluorPlus, Tecan, Crailsheim, Germany). A calibration line
constructed from different dilutions of 1 mM p-nitrophenol (pNp)
stock solution was used to calculate the amount of pNp produced by
the cell lysate which was then related to the respective cell number to
determine the speciﬁc ALP activity in μmol pNp/30 min/106 cells.
For evaluation of mineralization BMSCs were cultured for up to
28 days, washed with PBS and ﬁxed with 4% paraformaldehyde for
30 min. After two washing steps with distilled water, cells were stained
with 2% Alizarin Red S solution (Sigma-Aldrich®) for 3 min, washed
twice again and analyzed using an upright video microscope (Leica,
Wetzlar, Germany).2.5. Chondrogenic differentiation and immunohistological analysis
To induce chondrogenic differentiation, 1 × 106 BMSCs (passage
1)were centrifuged at 400 g and 4 °C for 10min and the resultingpellets
were cultured with chondrogenic (DMEM, 1% insulin transferrin seleni-
um, 100 μg/mL penicillin, 1000 μg/mL streptomycin, 10 ng/mL human
transforming growth factor beta-3, 10 nM dexamethasone, 210 μM
ascorbic acid) or control medium (DMEM, 1% ITS, 100 μg/mL penicillin,
1000 μg/mL streptomycin) for up to 14 days with the medium changed
twice a week. After 1, 7, and 14 days samples were frozen at−80 °C
until gene expression analysis. Histological sections were stained for
Collagen 2 using a mouse monoclonal antibody (ThermoScientiﬁc,
Cat.# MS-235-P, dilution 1:100). Antibody binding was detected by a
VECTASTAIN ABC Kit (Mouse IgG, Vector Laboratories, Cat.# PK-4002)
using 3,3′-diaminobenzidine (DAB, Sigma Aldrich, Cat.# D12384) as
substrate.
Table 1
Sociodemographic data (age, gender, and BMI) and scores of all probands; BMI, bodymass
index;WOMAC,Western Ontario andMcMaster Universities Osteoarthritis index; EQ-5D,
EuroQol-5D; HHS, Harris-Hip-Score.
OA
(n = 14)
Control
(n = 15)
P-value
Age (years) 67 ± 6 61 ± 4 0.018
Gender (f/m) 6/8 14/1 0.005
BMI (kg/m2) 28 25 0.176
WOMAC total (%) 47 ± 18 98 ± 3 b0.0001
WOMAC subscore pain (%) 41 ± 39 98 ± 3 b0.0001
WOMAC subscore stiffness (%) 80 ± 28 95 ± 10 0.256
WOMAC subscore everyday life activity (%) 45 ± 20 99 ± 3 b0.0001
EQ-5D (points) 64 ± 12 94 ± 8 b0.0001
HHS (points) 51 ± 15 100 ± 0.4 b0.0001
HHS performance test (points) 123 ± 37 231 ± 25 b0.0001
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For adipogenic differentiation BMSCs (passage 1) were cultivated in
basic medium containing adipogenic supplements (1 μM dexametha-
sone, 500 μM3-isobutyl-1-methylxanthine, 1 μg/mL insulin, 100 μM in-
domethacin) while cells cultured in basic medium served as controls.
After 1, 7, 14 and 21 days BMSCs were harvested for marker gene
expression analysis. Oil Red O staining was performed by culturing
cells for 21 days in adipogenic medium, washing with PBS, ﬁxing with
1% paraformaldehyde for 60 min, incubating twice in 100% propylene
glycol (Fluka Chemika) for 3 min, staining with 1.5 mL heated Oil Red
O for 10 min at 60 °C, incubating with 1.5 mL 85% propylene glycol
for 5 min and washing twice with distilled water before analyzing the
samples using an upright video microscope (Leica).
2.7. RNA isolation and reverse transcription (RT)
Total RNA was extracted using the RNeasy Mini Kit and RNase free
Dnase (Qiagen, Hilden, Germany) according to the manufacturer's pro-
tocol. RNA concentration was measured with a Nano drop ND-1000
spectrophotometer (PeqLab, Erlangen, Germany) before storing the ex-
tracted RNA at−80 °C for later analysis. CDNA synthesiswas performed
using the High Capacity cDNA Reverse Transcriptase Kit (Applied
Biosystems, Darmstadt, Germany) and the following cycling conditions:
10min at 25 °C, 120min at 37 °C, 5min at 85 °C and storing at 4 °C. After
measuring the concentration (Nano drop ND-1000 spectrophotometer)
cDNA was stored at −20 °C until quantitative real-time polymerase
chain reaction (qRT-PCR) analysis.
2.8. Quantitative RT-PCR
Quantitative RT-PCRwas performed in duplicate on aMx3000P real-
time PCR system (Stratagene, San Diego, California, USA) using 200 ng
of cDNA and Brilliant Sybr Green Master Mix (Stratagene, San Diego,
USA). Oligonucleotides were synthesized by Invitrogen™ and Euroﬁns
MWG synthesis GmbH (Ebersberg, Germany). The forward (F) and re-
verse (R) primer sequences read from 5′–3′ were as follows:
glycerinaldehyde-3-phosphate-dehydrogenase (GAPDH; GeneBank ac-
cession number: NM_001289745.1) = GAAGGTGAAGGTCGGAGTC
(F) and GAAGATGGTGATGGGATTTC (R), alkaline phosphatase (ALP,
GeneBank accession number: NM_001127501.2) = GACCCTTGACCC
CCACAAT (F) and GCTCGTACTGCATGTCCCCT (R), human bone
sialoprotein (BSP, GeneBank accession number: NM_004967.3) =
ACCACACTTTCTGCTACAAC (F) and CCTCTTCCTCCTCTTCTTCTTC (R),
runt-related transcription factor 2 (RUNX2, GeneBank accession num-
ber: NM_001024630.3) = GCCTTCAAGGTGGTAGCCC (F) and CGTTAC
CCGCCATGACAGTA (R), sex determining region Y-box 9 (SOX9,
GeneBank accession number: NM_000346.3) = TTCCGCGACGTGGA
CAT (F) and GGCGGCAGGTACTGGTCAAACTC (R), collagen, type X,
alpha 1 (COL10A1, GeneBank accession number: NM_000493.3) =
GCTAAGGGTGAAAGGGGTTC (F) and CTCCAGGATCACCTTTTGGA (R),
collagen, type II, alpha 1 (COL2A1, GeneBank accession number:
NM_033150.2) = GGCAATAGCAGGTTCACGTACA (F) and CGATAACA
GTCTTGCCCCACTT (R), human peroxisome proliferator activated recep-
tor gamma 2 (PPAR-γ, GeneBank accession number: NM_005037.5) =
TCTCCAGCATTTCTACTCCAC (F) and GGCTCCACTTTGATTGCAC (R),
human adipocyte fatty acid binding protein (FABP4, GeneBank acces-
sion number: NM_001442.2) = ACAGCACCCTCCTGAAAAC (F) and
GCAAAGCCCACTCCTACTTC (R).
qPCR reactions were performed with the following thermal proﬁle
95 °C for 10 min, followed by 40 cycles of 95 °C for 30 s, 60 °C for
1min and 72 °C for 1min.MxPro QPCR software was used to determine
the Ct for each ampliﬁcation reaction and results were exported to
Microsoft Excel for analysis. All PCR data were analyzed using the
2−ΔΔCt method and normalized against (GAPDH) as housekeeping
gene (Pfafﬂ, 2001).2.9. Fluorescence-activated cell sorting (FACS) analysis
BMSCs (passage 1) from each donor were detached after 2 days of
cultivation with 0.05% trypsin/0.02% EDTA (Invitrogen™), washed
with PBS, and distributed in 4 different samples to analyze CD34/
CD49/CD146, CD 5/CD73/CD105, CD14/CD90/CD106, and Stro1/
CD166, respectively. Fluorescein isothiocyanate (FITC)-coupled anti-
bodies against CD49, CD106 (BD Pharmingen™) and CD105 (AbD
Serotec, Düsseldorf, Germany), phycoerythrin (PE)-coupled antibodies
against CD146, CD73, CD14 and CD166 (BD Pharmingen™), as well as
allophycocyanin (APC)-coupled antibodies against CD34, CD45, CD90
(BD Pharmingen™) and Stro-1 (Biolegend, San Diego, California, USA)
were used for analysis. BMSCs were incubated with 4 μL of each anti-
body for 30 min in the dark, washed with PBS and ﬁxed with 200 μL
1% paraformaldehyde for 10 min before adding 200 μL PBS. The total
volume/tube was 500 μL and 10,000 BMSCs/tube were counted using
a BD LSRII ﬂow cytometer (BD Biosciences, San Jose, California, USA).
Unstained BMSCs incubated with APC, PE or FITC served as negative
controls. For expression analysis of selected BMSC-associated surface
markers percentages of positive cells and mean ﬂuorescence intensities
(MFI) were determined. Annexin V/propidium iodide assay was used
to analyze apoptosis (Sigma-Aldrich, St. Louis, Missouri, Vereinigte
Staaten; Molecular Probes, Eugene, Oregon, Vereinigte Staaten). Data
were analyzed using BD FACSDiva™ and FlowJo software (Miltenyi
Biotec GmbH, Bergisch Gladbach, Germany).
2.10. Statistical analyses
Numerical data were statistically analyzed using GraphPad Prism
5.04 software (San Diego, CA, USA). All values are expressed as
mean± standard deviation. Statistical analysiswas performed on quan-
tiﬁed data using One-way or Two-way ANOVA followed by Bonferroni's
multiple comparison post hoc test (two-sided). A p-value b0.05 was
considered signiﬁcant.
3. Results
3.1. Patient characteristics
Algofunctional scores of 14 patients with advanced-stage idiopathic
hip osteoarthritic (Kellgren and Lawrence grade 3 or 4, mean age 67 ±
6 years) and 15 age-matched (61 ± 4 years) healthy donors were
analyzed. The BMI was comparable in both groups. As expected
algofunctional scores (total WOMAC, EQ-5D, HHS) of osteoarthritic do-
nors were lower compared to healthy donors (p b 0.0001) andWOMAC
subscores demonstrated higher interindividual variation in the osteoar-
thritic group (Table 1). Normal joint function was demonstrated by
physiological total HHS scores of the healthy individuals in relation to
OA patients (mean ± SD, 100 ± 4 versus 51 ± 15 points). The HHS
functional subscore level was signiﬁcantly decreased, suggesting
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(123/300 vs. 231/300 points, p b 0.0001).
3.2. Colony forming efﬁciency and cell proliferation
No signiﬁcant intergroup differences were observed concerning the
ability to form colonies (Fig. 2A; mean ± SD, OA vs. control; N4 mm:
control: 4.0 ± 3.8, OA: 2.8 ± 2.1; 3–4 mm: control: 8.4 ± 6.1, OA:
12.0 ± 8.9; ≤2 mm: control: 13.5 ± 14.2, OA: 21.5 ± 9.6; Fig. 2B;
mean ± SD, OA vs. control; control: 25.9 ± 20.0, OA: 36.4 ± 18.3). As
illustrated in Fig. 2A and B the colony size and total colony number
did not differ signiﬁcantly in the OA group compared to healthy donors.
In respect of increase in cell number after 14 days of cultivation (Fig. 2C;
mean± SD, OA vs. control; 21.0± 13.2, OA: 22.7± 19.2) no signiﬁcant
intergroup differences were observed.
3.3. Cell viability and surface marker expression
Concerning cell viability no signiﬁcant differences between BMSCs
from osteoarthritic versus healthy donors were detected (Fig. 1A,
mean ± SD, control: day 1 89.8 ± 31.0%, day 4 92.3 ± 30.8%, day 7
88.5 ± 30.2%, day 11 85.2 ± 29.8%, day 14 85.8 ± 29.3%, OA: day 1
84.8 ± 31.6%, day 4 87.6 ± 30.3%, day 7 91.6 ± 31.7%, day 11 88.5 ±
32.5%, day 14 90.0 ± 31.3%). Expression levels of CD73, CD90, and
STRO-1were elevated compared to the negative control cellular surface
antigens CD14, CD34, and CD45 in BMSCs derived from both osteoar-
thritic and healthy donors (p b 0.0001). Interestingly, OA-BMSCs
showed decreased levels of CD166 (p b 0.001) and increased levels of
CD90 (p b 0.01) expression compared to cells from healthy donors
(Fig. 1B).
3.4. Osteogenic differentiation
As demonstrated in Fig. 3A the expression levels of the osteogenic
marker genes ALP (x-fold expression OA vs. control, mean ± SEM,
3.3 ± 0.7 vs. 2.7 ± 0.6), BSP (11.6 ± 4.1 vs. 7.2 ± 2.9), and RUNX2
(1.9±0.2 vs. 2.0± 1.3) did not differ signiﬁcantly in the OA and control
groups. Furthermore, no signiﬁcant intergroup differences were identi-
ﬁed concerning ALP activity after 14 days of cultivation with osteogenic
supplements (Fig. 3B, mean ± SD, control: 2.12 ± 2.98, OA: 2.13 ±
1.96). Moreover, the mineralization potential of BMSCs of both OA and
control groups was comparable as assessed by Alizarin Red staining
(Fig. 3C, D).
3.5. Chondrogenic differentiation
BMSCs from OA patients showed signiﬁcantly higher SOX9 gene
expression levels after 14 days of chondrogenic differentiation asFig. 1. A, Percentage of viable cells from healthy (black squares) and osteoarthritic (OA; whit
expression of BMSCs from healthy (control; black squares) and OA (white rhombuses) donors
CD, cluster of differentiation.compared to control cells (Fig. 4A, mean ± SEM, control: 0.99 ± 0.19,
OA: 2.01±0.28, **p=0.0037). A trend towards increased gene expres-
sion levels of COL2A1 and COL10A1was observed in OA-BMSCs as com-
pared to controls (Fig. 4A,mean±SEM, control: COL10A1 19.63±3.45,
COL2A1 1.21 ± 0.29, OA: COL10A1 33.06 ± 6.57, COL2A1 2.46 ± 0.71).
Collagen II staining of BMSCs after 14 days of chondrogenic cultivation
was comparable for OA- and control-BMSCs (Fig. 4B, C).
3.6. Adipogenic differentiation
No signiﬁcant intergroup differences were observed concerning the
expression of the adipogenic marker genes PPARγ and FABP4 (Fig. 5A,
mean ± SEM, control: PPARγ 5.45 ± 1.09, FABP4 3092 ± 485.2, OA:
PPARγ 5.13±0.90, FABP4 4036±1204) or lipid-rich vacuole formation
as assessed by Oil Red O staining (Fig. 5B, C).
4. Discussion
In the present study we compared proliferation, trilineage differen-
tiation potential, and surface marker expression of BMSCs isolated
from patients with idiopathic advanced-stage hip OA and from healthy
age-matched individuals. The main ﬁndings are that on the one hand,
the proliferative capacity of OA-BMSCs did not differ signiﬁcantly from
that of cells derived from non-diseased probands. In contrast, we ob-
served signiﬁcantly elevated SOX9 gene expression and decreased
CD166 and increased CD90 surface marker expression levels in
OA-BMSCs suggesting disease-speciﬁc differences with respect to
chondrogenic differentiation and cell surface marker expression.
Amajor limitation of the study denotes the unequal gender distribu-
tion among the groups, which was accepted in line with the ambitious
recruitment protocol aiming at the inclusion of healthy volunteers un-
dergoing bonemarrow aspiration. Concerning BMI, age, and profession-
al education, however, no intergroup differences were observed and as
expected, individuals of the control group demonstrated signiﬁcantly
increased algofunctional scores as observed in WOMAC, EQ-5D, and
HHS.
Furthermore, the adipogenic and osteogenic differentiation assays
used are prone to artifact bearing the risks of false positive measure-
ments. Moreover, the surface markers used in the present study denote
only minimum requirements for the characterization of BMSCs. In this
context, the inclusion of more markers would have potentially in-
creased cellular characterization accuracy. Thus, the lack of conﬁrmato-
ry in vivo data is a limitation, and no direct conclusions concerning the
effect of OA on the in vivo regenerative potential of BMSCs can be
drawn. Future studies will address this issue.
Novel cell-based therapeutic platforms aim at the regeneration
of defective tissues. In addition to localized – often traumatic – lesions,
tissue defects arising from degenerative joint disease are a potentiale rhombuses) donors after 1, 4, 7, 14 days of cultivation (mean ± SD). B, Surface marker
as determined by FACS after 2 days of cultivation (mean ± SD), **p b 0.01; ***p b 0.001;
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tential to revolutionize healthcare being curative in contrast other cur-
rent concepts that are solely directed at the management of disease
symptoms. In this context, BMSCs are key cellular components. Most
studies available addressing cellular changes associated with OA focus
on cell types that are directly present within the joint, e.g. chondrocytes
and synoviocytes (Bijlsma et al., 2011). In contrast, in the present study,
we set out to evaluate potential alterations in BMSC function associated
with OA.
A single speciﬁc surface antigen sufﬁciently deﬁning the human
BMSC phenotype is not known so far (Chamberlain et al., 2007; Da
SilvaMeirelles et al., 2008; Tuli et al., 2003). In addition to plastic adher-
ence under standard culture conditions and trilineage differentiation
along the osteogenic, chondrogenic, and adipogenic lineage, the Inter-
national Society for Cellular Therapy (ISCT) proposes minimal criteria
for the expression and absence of BMSC-associated surface antigen
markers (Dominici et al., 2006). In the present study, next to plastic ad-
herence and trilineage differentiation we demonstrated positivity of
CD73, CD90, and CD105 and low expression levels of the hematopoietic
markers CD14, CD34, and CD45 in cells frombothOA and control groups
by use of ﬂow cytometry thereby meeting minimum requirements for
in vitro BMSC characterization. Interestingly, however, we observed
slightly increased levels of the negative BMSC markers CD34 and CD45
as well as decreased levels of the positive cell surface proteins CD73,
CD90, and CD105) if compared to the ISCT consensus requirements
(Dominici et al., 2006). This may be an effect of the cell culturing proto-
col. In line with our ﬁndings, Kolf et al. reported on the variability of
BMSC surface patterns for e.g. CD90, CD105, and CD34 (Kolf et al.,
2007). Consequently, future investigations will address this issue in
more detail. However, as the overall marker expression proﬁles be-
tween both groups were comparable in the present study, we expect
the results to be validwith respect to intergroup comparison. Evaluating
disease-speciﬁc intergroup changes in surface marker expression, we
found signiﬁcantly increased levels of CD90 and reduced expression of
CD166 in OA-BMSCs as compared to control BMSCs from non-
diseased individuals. CD90 is a small (molecular weight of 25–35 kDa)
cell surface glycoprotein involved in cell adhesion during tissue regen-
eration by promoting growth and differentiation of stem cells that has
been reported to be expressed on human MSCs (Kisselbach et al.,
2009). CD166, amember of the immunoglobulin superfamily expressed
on proliferating and migrating cells including human BMSCs, mediates
cell–cell interactions and has been proven suitable for distinction be-
tween BMSCs and ﬁbroblasts (Halfon et al., 2011). In this context,
other groups did not observe differences in CD90 and CD166 expression
between human MSCs derived from adult and fetal bone marrow,
umbilical cord blood, and placental tissues (Mareschi et al., 2006;
Pasquinelli et al., 2007; Zhou et al., 2003). Interestingly, Mareddy et al.
found no differences concerning CD166 and CD90 expression betweenFig. 2. A, Colony-forming unit-ﬁbroblast of BMSCs from healthy (black squares) and osteoart
forming unit-ﬁbroblast of BMSCs from healthy (black squares) and osteoarthritic (OA; white
(control) and OA donors after 14 days of cultivation without osteogenic supplements (mean ±fast- and slow-growing clones of bone marrow stromal cells from pa-
tients with osteoarthritis (Mareddy et al., 2007). Whereas Varma and
co-authors observed decreased CD166 expression in freshly isolated
versus long-term cultured adipose tissue-derived stem cells, (Varma
et al., 2007) Fickert et al. found passage-independent CD166 expression
levels in human BMSCs (Fickert et al., 2011). However, to the authors'
best knowledge, the current study is the ﬁrst report on altered expres-
sion of distinct stem cell-related surface antigens by osteoarthritis.
In order to assess the cellular proliferation potential colony forming
efﬁciency was determined. As we decided to apply a low suction vacu-
um pressure in order to minimize potential discomfort during bone
marrow harvest under local anesthesia in the control individuals the
achieved mean cell yields ranging from 26 to 36 CFU per 106 plated
cells into 25 cm2 ﬂasks (Fig. 2B) were in the lower range compared
with other studies (Castro-Malaspina et al., 1980; Kasten et al., 2008;
Mansilla et al., 2006). However, as the harvest protocol was standard-
ized and applied to all probands of both groups, cell numbers of
BMSCs from healthy and OA donors after 14 days of cultivation were
comparable (Fig. 2C). We noticed a trend towards higher proliferation
rate in the OA study group. Singh et al. demonstrated increased prolifer-
ative capacity of osteophyte-derived BMSCs compared to normal BMSCs
(Singh et al., 2008). Jones et al. examined CD271+multipotential stro-
mal cells from healthy and osteoarthritic trabecular bone and associat-
ed, contrary to this study, decreased cell proliferation but unchanged
osteogenic potential with disease (Jones et al., 2010).
No signiﬁcant differences between BMSCs from OA versus healthy
donors were observed concerning gene expression of ALP, BSP, and
RUNX2 (Fig. 3A). ALP activity was not signiﬁcantly stimulated by
donor-speciﬁc OA comorbidity (Fig. 3B). These ﬁndings are in line
with a study by Oreffo et al. who reported no signiﬁcant differences in
ALP activity in OA-BMSCs (Oreffo et al., 1998). In contrast to Morimoto
et al. who demonstrated increased ALP activity levels in BMSCs derived
from donors with rheumatoid arthritis upon osteogenic cultivation we
did not observe disease-speciﬁc changes in osteogenic differentiation
markers after cultivation with and without osteogenic supplements
(Morimoto et al., 2009).
Concerning the chondrogenic differentiation of progenitor cells the
seeding density is crucial. We therefore realized efﬁcient chondrogenic
differentiation of BMSCs by means of three-dimensional pellet culture.
We found no signiﬁcant differences in the expression of COL2A1 and
COL10A1 genes in OA- as opposed to control BMSCs. In contrast, OA-
BMSCs showed signiﬁcantly enhanced SOX9 gene expression levels
(p b 0.005) as well as a trend towards increased COL10A1 and COL2A1
expression after 14 days of cultivation (Fig. 4A).
Pathological changes in cartilage tissue hemostasis denote the
ﬁrst stage of a complex pathomechanism resulting in OA. In the context
of clinical cell therapeutic strategies exaggerated chondrogenic differ-
entiation susceptibility as observed in the present study may hamperhritic (OA; white rhombuses) donors after 14 days of cultivation. B, Cumulative colony-
rhombuses) donors after 14 days of cultivation. C, Cell numbers of BMSCs from healthy
SD). CFU-F, colony-forming unit-ﬁbroblast; control, control group; min., minute.
Fig. 3. A, Relative gene expression (x-fold of cultivation without osteogenic supplements) of osteogenic marker genes (ALP, BSP and RUNX2) after 14 days of cultivation for BMSCs of
healthy (control; white bars) and osteoarthritic (OA; gray bars) donors (mean ± SEM). B, ALP-activity of BMSCs from healthy (control, black squares) and OA (white rhombuses)
donors after 14 days of cultivation with osteogenic supplements; ALP, alkaline phosphatase; BSP, human bone sialoprotein; control, control group; GAPDH, glycerinaldehyde-3-
phosphate-dehydrogenase; min., minute; pNp, p-nitrophenol; RUNX2, runt-related transcription factor 2. C, Alizarin Red staining OA-BMSCs after 21 days of cultivation in osteogenic
medium. D, Alizarin Red staining of BMSCs from healthy donors (control) after 21 days of cultivation in osteogenic medium.
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level of chondrogenic markers bears the potential of cellular hypertro-
phy thereby excluding the use of BMSCs for chondrogenic tissue regen-
eration applications (Mueller and Tuan, 2008; Pelttari et al., 2008;
Yoneno et al., 2005).
Coleman et al. described a concurrent increase in ALP, collagen I, col-
lagen X, and osteopontin after application of growth differentiation
factor-5 indicating a transition of BMSC pellet cultures to hypertrophy
as a precursor to endochondral ossiﬁcation (Coleman et al., 2013). Mur-
phy et al. detected a reduced chondrogenic and adipogenic activity of
mesenchymal stem cells from patients with advanced OA (Murphy
et al., 2002). As opposed to our ﬁndings, Scharstuhl et al. found an ade-
quate chondrogenic differentiation response in BMSCs irrespective of
donor age and OA comorbidity (Scharstuhl et al., 2007). In contrast to
the present study these authors harvested BMSCs from the femoral
BM compartment of 98 patients with different OA etiologies, e.g. prima-
ry age-related OA, post-traumatic, joint dysplasia, rheumatoid arthritis,
and aseptic osteonecrosis. However, a healthy positive control group,
as is provided in the present study, is missing in these studies.Fig. 4. A, Relative gene expression (x-fold of cultivation without chondrogenic supplements)
healthy (control) and osteoarthritic (OA) donors (mean ± SEM), **p = 0.0037. B, Histologic c
chondrogenic medium C, Histologic collagen II staining of OA-BMSCs after 14 days of cultivati
X, alpha 1; GAPDH, glycerinaldehyde-3-phosphate-dehydrogenase; SOX9, sex determining regFurthermore, the adipogenic and osteogenic differentiation capacity
was not investigated by the authors. Instead, BMSC phenotype was
only assessed in 25 donors by using ﬂow cytometry and RT-PCR was
only partially implemented. Dudics et al. reported of BMSCs from pa-
tients with rheumatoid arthritis or OA possessing similar chondrogenic
potential as BMSCs isolated from healthy donors (Dudics et al., 2009).
Compared to the present study the donor number was lower and only
COL2A1 was analyzed by RT-PCR as a chondrogenic marker gene,
whereas the present study compares proliferation, differentiation, and
additionally surface marker expression in OA and age-matched healthy
donors in a larger study population by use of several marker genes.
Hence, contrary to Dudics and co-workers, our data suggest an impact
of OA on the chondrogenic differentiation potential of BMSCs. The in-
crease of SOX9 gene expression in BMSCs of OA donors indicates activa-
tion of the chondrogenic differentiation direction being considered
favorable with regard to OA-BMSC application in cartilage regeneration
therapy (Bernstein et al., 2010). To further enlighten the role of
OA-BMSC in cartilage regeneration the evaluation of relevant signal
transduction pathways is necessary. PPARγ and FABP4 were chosen asof chondrogenic marker genes (SOX9, COL10A1 and COL2A1) after 14 days of BMSCs of
ollagen II staining of BMSCs from healthy donors (control) after 14 days of cultivation in
on in chondrogenic medium; COL2A1, collagen, type II, alpha 1; COL10A1, collagen, type
ion Y-box 9.
Fig. 5.A,Relative gene expression (x-fold of cultivationwithout adipogenic supplements) of adipogenicmarker genes (PPARγ and FABP4) after 14 days of BMSCsof healthy (control;white
bars) and osteoarthritic (OA; gray bars) donors (mean± SEM). B, Lipid rich vacuoles (stainedwith Oil Red O) of OA-BMSCs after 21 days of cultivation in adipogenic medium. C, Lipid rich
vacuoles (stained with Oil Red O) of BMSCs from healthy donors (control) after 21 days of cultivation in adipogenic medium. FABP4, human adipocyte fatty acid binding protein; GAPDH,
glycerinaldehyde-3-phosphate-dehydrogenase, PPARγ, human peroxisome proliferator-activated receptor gamma 2.
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et al., 2007; Dani, 1999; Gregoire et al., 1998). Justesen et al. found a
non-age related adipogenic differentiation capacity and PPARγ gene ex-
pression of BMSCs (Justesen et al., 2001). Our ﬁndings are in line with
this indicating an OA-independent PPARγ and FABP4 gene expression
proﬁle (Fig. 5A). In addition, lipid-rich vacuoles stained with Oil Red O
were detectable in both study groups in similar intensity (Fig. 5B, C).5. Conclusion
The proliferative capacity of bone marrow stromal cells is not inﬂu-
enced by OA. However, increased SOX9 and CD90 as well as reduced
CD166 expression levels inmusculoskeletal progenitor cells suggest dis-
tinct disease-speciﬁc cellular changes potentially corresponding to an
innate or reactively altered BMSC phenotype in patients affected by
OA. These data will help to further understand the role of BMSC in OA
and facilitate the application of autologous cell-based strategies for
musculoskeletal tissue regeneration in OA patients.Contributions
Conception and design: Stiehler, Bretschneider, Rauh, Vater, Jacobi.
Analysis and interpretation of the data: all co-authors.
Drafting of the article: Stiehler.
Critical revision of the article for important intellectual content:
Stiehler, Bünger, Günther.
Final approval of the article: Stiehler.
Provision of study materials or patients: all-coauthors.
Statistical expertise: Stiehler, Bretschneider, Rauh.
Obtaining of funding: Stiehler.
Administrative, technical, or logistic support: Bretschneider, Vater,
Rauh, Liebers.
Collection and assembly of data: Bretschneider, Liebers.Competing interests
The authors conﬁrm that there are no known conﬂicts of interest as-
sociatedwith this publication and there has beenno signiﬁcantﬁnancial
support for this work that could have inﬂuenced its outcome.Funding
This studywas ﬁnancially supported byGermanAcademic Exchange
Service/Federal Ministry of Education and Research (grant # D/09/
04774), Center for Regenerative Therapies Dresden (Seed Grant # 09-
08), Simon Fougner Hartmanns Family Foundation, Aase and Ejnar
Danielsens Foundation, Augustinus Foundation and Erik Hørslev og
hustru Birgit Hørslevs Foundation.
Acknowledgments
The authors are grateful to the following persons for their contribu-
tions (as mentioned) to this work: Katrin Müller and Suzanne Manthey
(technical assistance), Ulrich Schuler (establishing bonemarrow aspira-
tion protocol), Markus Sensenschmidt and Jan Mettelsiefen (physical
examination of probands), Kerstin Löbl (outpatient logistics), Brit
Brethfeld and Heike Voigt (data acquisition and management), and
Denis Corbeil (allocation of laboratory infrastructure).
References
Bernstein, P., Sticht, C., Jacobi, A., Liebers, C., Manthey, S., Stiehler, M., 2010. Expression
pattern differences between osteoarthritic chondrocytes and mesenchymal stem
cells during chondrogenic differentiation. Osteoarthr. Cartil. OARS Osteoarthr. Res.
Soc. 18, 1596–1607.
Bianco, P., Robey, P.G., Simmons, P.J., 2008. Mesenchymal stem cells: revisiting history,
concepts, and assays. Cell Stem Cell 2, 313–319.
Bijlsma, J.W.J., Berenbaum, F., Lafeber, F.P.J.G., 2011. Osteoarthritis: an update with rele-
vance for clinical practice. Lancet Lond. Engl. 377, 2115–2126.
Brooks, P.M., 2006. The burden of musculoskeletal disease — a global perspective. Clin.
Rheumatol. 25, 778–781.
Castro-Malaspina, H., Gay, R.E., Resnick, G., Kapoor, N., Meyers, P., Chiarieri, D., McKenzie,
S., Broxmeyer, H.E., Moore, M.A., 1980. Characterization of human bone marrow
ﬁbroblast colony-forming cells (CFU-F) and their progeny. Blood 56, 289–301.
Chamberlain, G., Fox, J., Ashton, B., Middleton, J., 2007. Concise review: mesenchymal
stem cells: their phenotype, differentiation capacity, immunological features, and
potential for homing. Stem Cells Dayt. Ohio 25, 2739–2749.
Coleman, C.M., Vaughan, E.E., Browe, D.C., Mooney, E., Howard, L., Barry, F., 2013. Growth
differentiation factor-5 enhances in vitro mesenchymal stromal cell chondrogenesis
and hypertrophy. Stem Cells Dev. 22, 1968–1976.
Da Silva Meirelles, L., Caplan, A.I., Nardi, N.B., 2008. In search of the in vivo identity of
mesenchymal stem cells. Stem Cells Dayt. Ohio 26, 2287–2299.
Dani, C., 1999. Embryonic stem cell-derived adipogenesis. Cells Tissues Organs 165,
173–180.
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F., Krause, D., Deans, R.,
Keating, A., Prockop, D., Horwitz, E., 2006. Minimal criteria for deﬁning multipotent
mesenchymal stromal cells. The International Society for Cellular Therapy position
statement. Cytotherapy 8, 315–317.
789M. Stiehler et al. / Stem Cell Research 16 (2016) 782–789Dudics, V., Kunstár, A., Kovács, J., Lakatos, T., Géher, P., Gömör, B., Monostori, E., Uher, F.,
2009. Chondrogenic potential of mesenchymal stem cells from patients with rheu-
matoid arthritis and osteoarthritis: measurements in amicroculture system. Cells Tis-
sues Organs 189, 307–316.
Fickert, S., Schröter-Bobsin, U., Gross, A.-F., Hempel, U., Wojciechowski, C., Rentsch, C.,
Corbeil, D., Günther, K.P., 2011. Human mesenchymal stem cell proliferation and os-
teogenic differentiation during long-term ex vivo cultivation is not age dependent.
J. Bone Miner. Metab. 29, 224–235.
Gregoire, F.M., Smas, C.M., Sul, H.S., 1998. Understanding adipocyte differentiation.
Physiol. Rev. 78, 783–809.
Halfon, S., Abramov, N., Grinblat, B., Ginis, I., 2011. Markers distinguishing mesenchymal
stem cells from ﬁbroblasts are downregulated with passaging. Stem Cells Dev. 20,
53–66.
Intema, F., Hazewinkel, H.A.W., Gouwens, D., Bijlsma, J.W.J., Weinans, H., Lafeber, F.P.J.G.,
Mastbergen, S.C., 2010. In early OA, thinning of the subchondral plate is directly relat-
ed to cartilage damage: results from a canine ACLT-meniscectomymodel. Osteoarthr.
Cartil. OARS Osteoarthr. Res. Soc. 18, 691–698.
Jones, E., English, A., Churchman, S.M., Kouroupis, D., Boxall, S.A., Kinsey, S., Giannoudis,
P.G., Emery, P., McGonagle, D., 2010. Large-scale extraction and characterization of
CD271+multipotential stromal cells from trabecular bone in health and osteoarthritis:
implications for bone regeneration strategies based on uncultured or minimally
cultured multipotential stromal cells. Arthritis Rheum. 62, 1944–1954.
Justesen, J., Stenderup, K., Ebbesen, E.N., Mosekilde, L., Steiniche, T., Kassem, M., 2001.
Adipocyte tissue volume in bone marrow is increased with aging and in patients
with osteoporosis. Biogerontology 2, 165–171.
Kasten, P., Beyen, I., Egermann, M., Suda, A.J., Moghaddam, A.A., Zimmermann, G.,
Luginbühl, R., 2008. Instant stem cell therapy: characterization and concentration of
human mesenchymal stem cells in vitro. Eur. Cell. Mater. 16, 47–55.
Kellgren, J., Lawrence, J., 1963. Atlas of Standard Radiographs: The Epidemiology of
Chronic Rheumatism. 2 ed. Blackwell Scientiﬁc, Oxford.
Kisselbach, L., Merges, M., Bossie, A., Boyd, A., 2009. CD90 expression on human primary
cells and elimination of contaminating ﬁbroblasts from cell cultures. Cytotechnology
59, 31–44.
Kolf, C.M., Cho, E., Tuan, R.S., 2007. Mesenchymal stromal cells. Biology of adult mesen-
chymal stem cells: regulation of niche, self-renewal and differentiation. Arthritis
Res. Ther. 9, 204.
Learmonth, I.D., Young, C., Rorabeck, C., 2007. The operation of the century: total hip re-
placement. Lancet Lond. Engl. 370, 1508–1519.
Mansilla, E., Marín, G.H., Drago, H., Sturla, F., Salas, E., Gardiner, C., Bossi, S., Lamonega, R.,
Guzmán, A., Nuñez, A., et al., 2006. Bloodstream cells phenotypically identical to
human mesenchymal bone marrow stem cells circulate in large amounts under the
inﬂuence of acute large skin damage: new evidence for their use in regenerative
medicine. Transplant. Proc. 38, 967–969.
Mareddy, S., Crawford, R., Brooke, G., Xiao, Y., 2007. Clonal isolation and characterization
of bone marrow stromal cells from patients with osteoarthritis. Tissue Eng. 13,
819–829.
Mareschi, K., Ferrero, I., Rustichelli, D., Aschero, S., Gammaitoni, L., Aglietta, M., Madon, E.,
Fagioli, F., 2006. Expansion of mesenchymal stem cells isolated from pediatric and
adult donor bone marrow. J. Cell. Biochem. 97, 744–754.Mobasheri, A., Kalamegam, G., Musumeci, G., Batt, M.E., 2014. Chondrocyte and mesen-
chymal stem cell-based therapies for cartilage repair in osteoarthritis and related
orthopaedic conditions. Maturitas 78, 188–198.
Morimoto, D., Kuroda, S., Kizawa, T., Nomura, K., Higuchi, C., Yoshikawa, H., Tomita, T.,
2009. Equivalent osteoblastic differentiation function of human mesenchymal stem
cells from rheumatoid arthritis in comparison with osteoarthritis. Rheumatol. Oxf.
Engl. 48, 643–649.
Mueller, M.B., Tuan, R.S., 2008. Functional characterization of hypertrophy in chondrogen-
esis of human mesenchymal stem cells. Arthritis Rheum. 58, 1377–1388.
Murphy, J.M., Dixon, K., Beck, S., Fabian, D., Feldman, A., Barry, F., 2002. Reduced
chondrogenic and adipogenic activity of mesenchymal stem cells from patients
with advanced osteoarthritis. Arthritis Rheum. 46, 704–713.
Oreffo, R.O., Bennett, A., Carr, A.J., Trifﬁtt, J.T., 1998. Patients with primary osteoarthritis
show no change with ageing in the number of osteogenic precursors. Scand.
J. Rheumatol. 27, 415–424.
Pasquinelli, G., Tazzari, P., Ricci, F., Vaselli, C., Buzzi, M., Conte, R., Orrico, C., Foroni, L.,
Stella, A., Alviano, F., et al., 2007. Ultrastructural characteristics of human mesenchy-
mal stromal (stem) cells derived from bone marrow and term placenta. Ultrastruct.
Pathol. 31, 23–31.
Pelttari, K., Steck, E., Richter, W., 2008. The use of mesenchymal stem cells for chondro-
genesis. Injury 39 (Suppl. 1), S58–S65.
Pfafﬂ, M.W., 2001. A new mathematical model for relative quantiﬁcation in real-time
RT-PCR. Nucleic Acids Res. 29, e45.
Pittenger, M.F., Mackay, A.M., Beck, S.C., Jaiswal, R.K., Douglas, R., Mosca, J.D., Moorman,
M.A., Simonetti, D.W., Craig, S., Marshak, D.R., 1999. Multilineage potential of adult
human mesenchymal stem cells. Science 284, 143–147.
Rauh, J., Milan, F., Günther, K.-P., Stiehler, M., 2011. Bioreactor systems for bone tissue
engineering. Tissue Eng. Part B Rev. 17, 263–280.
Scharstuhl, A., Schewe, B., Benz, K., Gaissmaier, C., Bühring, H.-J., Stoop, R., 2007.
Chondrogenic potential of human adult mesenchymal stem cells is independent of
age or osteoarthritis etiology. Stem Cells Dayt. Ohio 25, 3244–3251.
Singh, S., Jones, B.J., Crawford, R., Xiao, Y., 2008. Characterization of a mesenchymal-like
stem cell population from osteophyte tissue. Stem Cells Dev. 17, 245–254.
Tuli, R., Tuli, S., Nandi, S., Wang, M.L., Alexander, P.G., Haleem-Smith, H., Hozack, W.J.,
Manner, P.A., Danielson, K.G., Tuan, R.S., 2003. Characterization of multipotential
mesenchymal progenitor cells derived from human trabecular bone. Stem Cells
Dayt. Ohio 21, 681–693.
Varma, M.J.O., Breuls, R.G.M., Schouten, T.E., Jurgens, W.J.F.M., Bontkes, H.J., Schuurhuis,
G.J., van Ham, S.M., van Milligen, F.J., 2007. Phenotypical and functional characteriza-
tion of freshly isolated adipose tissue-derived stem cells. Stem Cells Dev. 16, 91–104.
Yoneno, K., Ohno, S., Tanimoto, K., Honda, K., Tanaka, N., Doi, T., Kawata, T., Tanaka, E.,
Kapila, S., Tanne, K., 2005. Multidifferentiation potential of mesenchymal stem cells
in three-dimensional collagen gel cultures. J. Biomed. Mater. Res. A 75, 733–741.
Zhou, D., Huang, S., Wu, Y.-F., Wei, J., Chen, G., Li, Y., Bao, R., 2003. [The expansion and
biological characteristics of human mesenchymal stem cells]. Zhonghua Er Ke Za
Zhi Chin. J. Pediatr. 41, 607–610.
